Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour
necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune …

Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that
has changed the management of inflammatory bowel diseases. Our review describes its …

Infliximab is a monoclonal antibody against tumor necrosis factor alpha (TNF-α), which is
approved for the treatment of chronic inflammatory bowel disease (IBD) such as Crohn's …

Infliximab | BioDrugs Skip to main content SpringerLink Account Menu Find a journal Publish
with us Track your research Search Cart 1.Home 2.BioDrugs 3.Article Infliximab An Updated …

Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor
(TNF)-α that has shown efficacy in Crohn's disease and rheumatoid arthritis with a disease …

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract. The disease
can be quite severe, resulting in hospitalisation, requiring long-term treatment with a variety …

Infliximab (IFX) has tremendously enriched the therapy of inflammatory bowel diseases
(IBD) and other immune mediated diseases. Although the efficacy of IFX was undoubtedly …

In this large series, the investigators evaluated the short-and long-term safety of infliximab in
patients with Crohn's disease. Using pharmacy records, 500 patients with Crohn's disease …

Infliximab was first introduced in Europe in 1999 for Crohn's disease. During the following
decade major progress was made in the understanding of the pathophysiology of …

Opinion statement Crohn's disease (CD) and ulcerative colitis (UC) are chronic and often
debilitating inflammatory bowel diseases (IBD) without medical cures. Despite the existence …